A new test that can revolutionize the subsequent care of thousands of breast cancer patients – Irish news

Scientists have developed a new test for some breast cancer patients who can predict whether or not their cancer will return just after only two weeks after the start of treatment.

Experts said that thousands of breast cancer patients can be saved in unnecessary treatment as a result.

The new test was developed to detect the possibility of cancer frequency in patients with a type of breast cancer known as positive estrogen receptors, human skin growth receptors 2 positive – which represent about 200,000 cases of cancer every year all over the world.

Writing in Ebiomicine magazine, experts said the test means that some patients will be able to “cancel the escalation” of their treatment while it can also help identify those who need “more intense therapeutic strategies.”

The test, which was developed by scientists at the Cancer Research Institute, London, properly determines 6 % of patients at risk of relapse.

The researchers analyzed the tumor samples from 213 patients.

They found that two weeks of hormonal therapy changes the properties of some tumors, causing its sub -type to change.

Patients with the highest risk of cancer returning had a type of tumor called shit B, which has not yet changed this short -term hormonal therapy.

Experts said these patients will need more intense treatment.

They said the results highlight the benefit of two weeks of hormonal therapy before surgery to help direct decisions to doctors.

“To truly personal care, we need to improve how breast cancer is classified, so that every patient is likely to receive treatment for their favor,” said London, the author, London.

“Although the current classification depends on hormone receptors and Her2 case, we know that patients within these groups can respond completely differently to the same treatment.

“Our previous research has identified the distinctive molecular sub -species within the positive breast cancer of estrogen receptors. In this new study, we have shown that these sub -species can be transformed after only two weeks of hormonal therapy.

“This insight helps us to identify patients who are likely to respond well, which may show early signs to resist treatment, providing an opportunity to adapt treatment strategies sooner.

“Ultimately, our results are approaching more accurate care that focuses on the patient for this sub -type breast cancer.”

Professor Christian Helen, CEO of the Cancer Research Institute, added, “By decoding the basic biology of tumors, we can allocate treatments for individual patients,” added Professor Christian Helen, CEO of the Cancer Research Institute.

“These results add increased evidence that genetic tests can play a strong role in helping to predict the risk of developing breast cancer, especially in people with positive ER2 breast cancer,” said Dr. Simon Vincent, the chief scientific official in breast cancer now, who has financed the study in part.

“There is a possibility that women will greatly benefit from this research in the future, as it ensures that it avoids undergoing unnecessary treatment and leads to treatment plans for more personalities, so that women receive the most effective treatment for their specified type of breast cancer.”